Moderna (MRNA) Vaccine Effectiveness Case

D. Massachusetts

Court

1:24-cv-12058

Case number

01/18/2023

Class period Start

06/25/2024

Class period End

10/08/2024

Lead Plaintiff motion deadline

$MRNA stockholders filed a claim against Moderna for misleading them about the effectiveness of its vaccine, overstating its potential.
After the news about the vaccine on June 26, 2024, $MRNA fell by 11%.
Moderna investors can join this case to be notified about potential recovery.
Case Details:

On May 31, 2024, Moderna's FDA-approved RSV vaccine showed a 78.7% efficacy, lower than the expected 83.7%.

On this news, $MRNA fell 5.9% on May 31, 2024.

Then, on June 26, 2024, Moderna revealed that its RSV vaccine’s effectiveness dropped to around 50% after 18 months, lower than competitors' vaccines.

After that, $MRNA fell 11% on the same day.

Based on these events, a $MRNA stockholder filed a claim against Moderna and its leaders, accusing them of the following:
Moderna's mRNA-1345 vaccine was less effective than claimed.
As a result, its clinical and commercial potential was overstated.
Considering all the representations, investors suspect Moderna misled them about the effectiveness of its vaccine, overstating its potential.

Case Status

Lead Plaintiff Submission

Alleged Offence

Mismanagement,

Misleading Statements,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

05/02/2024

Filing date

08/09/2024

Lead Plaintiff Deadline

10/08/2024

Moderna (MRNA) Vaccine Effectiveness Case

Collecting participants…